id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12810 R48233 |
Meador (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 | Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) | 3rd trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: Yes extrapolated (cont. endpoint) |
2.58 [0.50;13.27] excluded (control group) |
-/5 -/93 | - | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12811 R48234 |
Meador (Topiramate) (Controls unexposed, disease free), 2021 | Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) | 3rd trimester | prospective cohort | unexposed, disease free | Adjustment: Yes extrapolated (cont. endpoint) | 2.49 [0.48;12.82] | -/5 -/87 | - | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10103 R36820 |
Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Visits to a speech therapist (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.20 [0.80;1.80] excluded (control group) |
33/477 157/2,916 | 190 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8613 R28742 |
Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 | Health care utilization: Speech therapy (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.40 [1.00;2.00] | 33/477 72,012/1,710,441 | 72,045 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8583 R28561 |
Husebye (Topiramate) (Controls exposed to Lamotrigine, sick), 2020 | Language impairment age 8 years (Language 20) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
1.19 [0.11;12.82] C excluded (control group) |
1/4 9/41 | 10 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8584 R28563 |
Husebye (Topiramate) (Controls unexposed, disease free), 2020 | Language impairment age 8 years (Language 20) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: Yes |
1.10 [0.10;10.90] excluded (control group) |
1/4 8,250/42,550 | 8,251 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8585 R28565 |
Husebye (Topiramate) (Controls unexposed, sick), 2020 | Language impairment age 8 years (Language 20) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.10 [0.11;10.87] C | 1/4 35/150 | 36 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8582 R28544 |
Bromley (Topiramate), 2016 | Verbal abilities <85 (Wechsler Preschool and Primary Scale of Intelligence (WPPSI) / Wechsler Intelligence Scale for Children (WISC)) (5-9 years old) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 1.59 [0.33;7.69] C | 3/27 4/55 | 7 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8615 R28766 |
Rihtman (Topiramate) (Mixed indications), 2012 | Verbal IQ (Stanford Binet) (mean age around 4 years old) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) Matched | 5.71 [1.23;26.53] | -/9 -/18 | - | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.52 [1.10;2.10] | 72,088 | 522 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Topiramate) (Controls unexposed, disease free; 2: Topiramate) (Controls unexposed, NOS) (Mixed indications; 3: Topiramate) (Controls unexposed, sick; 4: Topiramate; 5: Topiramate) (Mixed indications;
Asymetry test p-value = 0.3179 (by Egger's regression)
slope=0.2241 (0.2194); intercept=0.7164 (0.5995); t=1.1950; p=0.3179
excluded 10103, 8583, 8584, 12810